BioCentury
ARTICLE | Clinical News

CureXcell: Phase III data

August 24, 2015 7:00 AM UTC

Macrocure said a pre-specified futility analysis by a DSMB of the double-blind, U.S. Phase III MC-105 trial in 265 patients with chronic venous leg ulcers showed that CureXcell given about every 4 wee...